Published in J Virol on March 30, 2011
N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. J Virol (2012) 0.96
A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b. J Virol (2014) 0.76
Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo. J Infect Dis (2015) 0.75
Complement Evasion Strategies of Viruses: An Overview. Front Microbiol (2017) 0.75
Idiosyncratic Mòjiāng virus attachment glycoprotein directs a host-cell entry pathway distinct from genetically related henipaviruses. Nat Commun (2017) 0.75
The complement system in regulation of adaptive immunity. Nat Immunol (2004) 4.58
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature (2005) 3.39
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Molecular biology of Hendra and Nipah viruses. Microbes Infect (2001) 2.33
Nipah virus: vaccination and passive protection studies in a hamster model. J Virol (2004) 2.09
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol (2006) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect (2010) 1.65
Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol (2002) 1.52
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol (2007) 1.48
A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F). J Biol Chem (2008) 1.44
Engineered antibodies with increased activity to recruit complement. J Immunol (2001) 1.40
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res (2008) 1.36
The emergence of Nipah virus, a highly pathogenic paramyxovirus. J Clin Virol (2008) 1.31
The relevance of complement to virus biology. Virology (2004) 1.29
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Recombinant nipah virus vaccines protect pigs against challenge. J Virol (2006) 1.25
Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog (2010) 1.25
Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. J Immunol (1977) 1.21
Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology (1981) 1.17
Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J Virol (2007) 1.17
Complement levels and activity in the normal and LPS-injured lung. Am J Physiol Lung Cell Mol Physiol (2006) 1.15
Emerging patterns in complement-mediated pathogen recognition. Cell (2006) 1.09
Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements. J Immunol (1978) 1.06
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods (2009) 0.96
Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther (2005) 0.95
Envelope-receptor interactions in Nipah virus pathobiology. Ann N Y Acad Sci (2007) 0.95
Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. Virology (2009) 0.93
The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J Virol (2009) 0.92
Developments towards effective treatments for Nipah and Hendra virus infection. Expert Rev Anti Infect Ther (2006) 0.90
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology (1988) 0.89
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature (2005) 3.39
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe (2011) 2.25
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood (2009) 2.07
N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol (2006) 1.97
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med (2005) 1.93
Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol (2005) 1.54
Naturally occurring substitutions in the P/V gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha/beta interferon synthesis and cell death. J Virol (2002) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol (2007) 1.48
Novel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokines. J Immunol (2005) 1.47
A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F). J Biol Chem (2008) 1.44
Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage. J Virol (2007) 1.44
Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A (2011) 1.40
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog (2010) 1.32
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol (2010) 1.23
Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology (2007) 1.22
Galectin-1-matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. J Immunol (2006) 1.17
Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr (2009) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells. Mol Microbiol (2006) 1.16
A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics. Virol J (2009) 1.15
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract. J Virol (2005) 1.09
Cysteines in the stalk of the nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation. J Virol (2012) 1.08
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry. PLoS Pathog (2013) 1.08
Paramyxovirus-induced shutoff of host and viral protein synthesis: role of the P and V proteins in limiting PKR activation. J Virol (2007) 1.08
Controllable hydrogen sulfide donors and their activity against myocardial ischemia-reperfusion injury. ACS Chem Biol (2013) 1.07
Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol (2004) 1.07
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
A simian virus 5 (SV5) P/V mutant is less cytopathic than wild-type SV5 in human dendritic cells and is a more effective activator of dendritic cell maturation and function. J Virol (2006) 1.07
Role for the phosphoprotein P subunit of the paramyxovirus polymerase in limiting induction of host cell antiviral responses. J Virol (2007) 1.06
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J Biol Chem (2004) 1.05
Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol (2007) 1.05
Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol (2013) 1.04
Triggering of the newcastle disease virus fusion protein by a chimeric attachment protein that binds to Nipah virus receptors. J Biol Chem (2011) 1.03
Expression of human immunodeficiency virus (HIV)-binding lectin DC-SIGNR: Consequences for HIV infection and immunity. Hum Pathol (2002) 1.03
Rho GTPase activity modulates paramyxovirus fusion protein-mediated cell-cell fusion. Virology (2006) 1.02
A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade. J Virol (2010) 1.01
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology (2011) 1.00
Fluorescent probes based on nucleophilic substitution-cyclization for hydrogen sulfide detection and bioimaging. Chemistry (2013) 1.00
Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol (2010) 0.97
Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods (2009) 0.96
N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. J Virol (2012) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
IFNgamma-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment. Virology (2010) 0.94
High avidity CD8+ T cells are the initial population elicited following viral infection of the respiratory tract. J Immunol (2003) 0.94
Growth sensitivity of a recombinant simian virus 5 P/V mutant to type I interferon differs between tumor cell lines and normal primary cells. Virology (2005) 0.94
Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol (2009) 0.93
Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. PLoS One (2013) 0.92
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol (2012) 0.92
The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J Virol (2009) 0.92
TLR-4 and -6 agonists reverse apoptosis and promote maturation of simian virus 5-infected human dendritic cells through NFkB-dependent pathways. Virology (2007) 0.92
Henipavirus receptor usage and tropism. Curr Top Microbiol Immunol (2012) 0.91
Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem (2009) 0.91
Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J Virol (2012) 0.91
A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon. J Virol (2008) 0.91
Virus growth and antibody responses following respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5. Virology (2008) 0.90
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Variants of the paramyxovirus Simian virus 5 with accelerated or delayed viral gene expression activate proinflammatory cytokine synthesis. Virology (2006) 0.90
Abortive versus productive viral infection of dendritic cells with a paramyxovirus results in differential upregulation of select costimulatory molecules. J Virol (2005) 0.90
Role for the paramyxovirus genomic promoter in limiting host cell antiviral responses and cell killing. J Virol (2009) 0.89
Detection of receptor-induced glycoprotein conformational changes on enveloped virions by using confocal micro-Raman spectroscopy. J Virol (2013) 0.89
Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J Virol (2008) 0.88
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology (2013) 0.88
Apoptosis induction and interferon signaling but not IFN-beta promoter induction by an SV5 P/V mutant are rescued by coinfection with wild-type SV5. Virology (2003) 0.88
Endothelial galectin-1 binds to specific glycans on nipah virus fusion protein and inhibits maturation, mobility, and function to block syncytia formation. PLoS Pathog (2010) 0.88
Regulation of the nucleocytoplasmic trafficking of viral and cellular proteins by ubiquitin and small ubiquitin-related modifiers. Biol Cell (2011) 0.87
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology (2013) 0.86
Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology (2013) 0.85
Individual N-glycans added at intervals along the stalk of the Nipah virus G protein prevent fusion but do not block the interaction with the homologous F protein. J Virol (2013) 0.85
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Pivotal Advance: Nonfunctional lung effectors exhibit decreased calcium mobilization associated with reduced expression of ORAI1. J Leukoc Biol (2010) 0.84
Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway. J Virol (2009) 0.83
Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol (2012) 0.83
Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways. Virology (2010) 0.83
TLR3-dependent upregulation of RIG-I leads to enhanced cytokine production from cells infected with the parainfluenza virus SV5. Virology (2009) 0.83